What are the latest guidelines for managing hypertension?
Reading File
Finding Sources
Searching PubMed
"hypertension"[MeSH Terms] AND "guideline"[pt]
Searching the Web
hypertension management guidelines 2024 2025 AHA ACC ESH
Reading Article
Reading Article
Reading Web Page
hypertension guidelines 2025 treatment targets drug therapy lifestyle
I now have comprehensive, current data from both the 2025 AHA/ACC and 2024 ESC guidelines. Here's a thorough synthesis:
Latest Hypertension Management Guidelines (2025)
There are two landmark current guidelines: the 2025 AHA/ACC Guideline (published August 2025, replaces 2017) and the 2024 ESC Guideline. Key recommendations from both are summarized below.
1. Blood Pressure Classification & Thresholds
| Category | Systolic | Diastolic |
|---|---|---|
| Normal | < 120 | < 80 |
| Elevated / High-normal | 120–129 | < 80 |
| Stage 1 HTN | 130–139 | 80–89 |
| Stage 2 HTN | ≥ 140 | ≥ 90 |
The 2025 AHA/ACC retains the 130/80 mmHg diagnostic threshold from the 2017 guideline. The 2024 ESC uses ≥ 140/90 mmHg as the formal hypertension threshold but classifies 130–139/85–89 as "high-normal" warranting close surveillance.
2. Treatment Targets
- Universal goal (AHA/ACC 2025): < 130/80 mmHg for most adults
- Exceptions: institutionalized older adults, limited life expectancy, pregnancy
- 2024 ESC: < 140/90 mmHg as the universal minimum; < 130/80 mmHg in most patients who can tolerate it; higher targets (< 140–150/90) acceptable in frail elderly
3. Risk Stratification — Key Change (AHA/ACC 2025)
The PREVENT™ calculator (Predicting Risk of Cardiovascular Disease EVENTs) replaces the Pooled Cohort Equation. This shift reflects multi-organ lifetime risk (cardiovascular, renal, cognitive) rather than short-term ASCVD probability alone.
When to initiate drug therapy:
- BP ≥ 140/90 mmHg → pharmacotherapy indicated regardless of risk
- BP 130–139/80–89 mmHg → pharmacotherapy for patients with:
- Established CVD or prior stroke
- Diabetes mellitus
- Chronic kidney disease (CKD)
- 10-year CVD risk ≥ 7.5% by PREVENT™
- Lower-risk patients with BP 130–139/80–89: trial of lifestyle therapy for 3–6 months before initiating medications
4. Lifestyle Modifications (Foundational for All)
These remain first-line for all stages:
- DASH diet (rich in fruits, vegetables, low-fat dairy, reduced sodium)
- Dietary sodium reduction (< 1.5 g/day optimal; < 2.3 g/day minimum)
- Weight loss (each 1 kg loss ≈ 1 mmHg reduction)
- Physical activity: ≥ 150 min/week moderate aerobic or 75 min/week vigorous
- Moderation of alcohol (≤ 1 drink/day for women, ≤ 2 for men)
- Smoking cessation
5. Pharmacotherapy
First-Line Agents (Race-Neutral Selection — AHA/ACC 2025)
The 2025 guideline removes race-based prescribing (e.g., calcium channel blockers for Black patients as preferred) in favor of individualized, evidence-based selection:
| Drug Class | Notes |
|---|---|
| Thiazide/thiazide-like diuretics (chlorthalidone, HCTZ) | First-line for most |
| ACE inhibitors (e.g., lisinopril) | Preferred with CKD/diabetes/proteinuria |
| Angiotensin receptor blockers (ARBs) | Alternative to ACEi; do NOT combine with ACEi |
| Dihydropyridine calcium channel blockers (amlodipine) | Effective across all demographics |
Stage 2 Hypertension (BP ≥ 140/90)
- Preferred: single-pill dual-class fixed-dose combinations (FDCs) to improve adherence and accelerate BP control
Combinations to Avoid
- Do not combine ACEi + ARB (increased adverse effects, no added benefit)
- Do not use ACEi/ARB in pregnancy
6. Special Populations
| Population | Key Recommendation |
|---|---|
| CKD | ACEi or ARB preferred; target < 130/80 mmHg |
| Diabetes | Target < 130/80; ACEi/ARB if albuminuria |
| Heart failure | Beta-blockers + ACEi/ARB/ARNI + diuretics + MRA |
| Older adults (frail) | ESC suggests < 140–150/90; avoid over-treatment |
| Pregnancy | ACEi/ARB contraindicated; labetalol, nifedipine, methyldopa preferred |
| Resistant HTN | Screen for primary aldosteronism (now recommended for all Stage 2 HTN per ESC 2024 and AHA/ACC 2025) |
7. Key New Themes (2025)
- Team-based, multidisciplinary care — nurses, pharmacists, community health workers — is explicitly recommended to address structural barriers to medication access
- Aldosterone screening broadened: screen all Stage 2 HTN (not just hypokalemia)
- Cognition and dementia recognized as hypertension-related end-organ damage
- BP measurement accuracy emphasized: validated devices, out-of-office monitoring (home/ambulatory) for diagnosis and management optimization
Sources
- 2025 AHA/ACC Guideline — Jones DW et al., Circulation 2025; PMID: 40811497
- 2024 ESC Guideline for Elevated Blood Pressure and Hypertension — McEvoy JW et al., European Heart Journal 2024; PMID: 39210715
Note: The 2025 AHA/ACC guideline (PMID: 40811497) has an associated erratum (PMID: 41973840) — check the published version for any corrections before clinical use.
This is a shared conversation. Sign in to Orris to start your own chat.